Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial
16. Dezember 2020 09:15 ET
|
Protagenic Therapeutics, Inc.
Clinical Trials of First-in-Class Peptide to Commence in 1H 2021 NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (OTCQB: PTIX) announced today that Dr. Maurizio Fava,...